Subscribe

Articles

I-SPY 2: Durvalumab plus Olaparib and Paclitaxel Triplet in High-Risk Breast Cancer “Graduates” to Phase 3 Study
I-SPY 2: Durvalumab plus Olaparib and Paclitaxel Triplet in High-Risk Breast Cancer “Graduates” to Phase 3 Study
By Phoebe Starr
AACR Highlights, Breast Cancer
TON - June 2020, Vol 13, No 3
“The idea behind the combination was to boost the immune response by adding an anti–PD-1 checkpoint inhibitor, since PARP inhibitors are known to increase the expression of the PD-L1 protein in the tumor,” said Lajos Pusztai, MD, DPhil. Read More ›
International Society of Cannabis Pharmacists Plans to Hold Inaugural Meeting in 2020
International Society of Cannabis Pharmacists Plans to Hold Inaugural Meeting in 2020
By Meg Barbor, MPH
Medical Marijuana
TON - June 2020, Vol 13, No 3
Read More ›
ASCO Publishes First Guideline on Use of Molecular Biomarkers in Localized Prostate Cancer
ASCO Publishes First Guideline on Use of Molecular Biomarkers in Localized Prostate Cancer
By Rebecca Bailey
Biomarkers, Prostate Cancer
TON - June 2020, Vol 13, No 3
The American Society of Clinical Oncology, in partnership with the European Association of Urology, the American Urological Association, and the College of American Pathologists, published a set of recommendations that offers further guide prostate cancer management. Read More ›
Gemcitabine-Cisplatin Combination a New Standard in Pancreatic Cancer with Germline BRCA or PALB2 Mutation
Gemcitabine-Cisplatin Combination a New Standard in Pancreatic Cancer with Germline BRCA or PALB2 Mutation
By Wayne Kuznar
Pancreatic Cancer
TON - June 2020, Vol 13, No 3
“The doublet is our recommendation for moving forward, and we believe these data define a reference regimen for germline BRCA-mutated, PALB2-mutated pancreas cancer,” said Eileen M. O’Reilly, MD. Read More ›
NCCN Issues Guidance for Cancer Care During the COVID-19 Pandemic
NCCN Issues Guidance for Cancer Care During the COVID-19 Pandemic
By Wayne Kuznar
COVID-19
TON - June 2020, Vol 13, No 3
Read More ›
Nivolumab-Based Chemotherapy Regimen Shows Activity in Muscle-Invasive Urothelial Cancer
Nivolumab-Based Chemotherapy Regimen Shows Activity in Muscle-Invasive Urothelial Cancer
By Phoebe Starr
Bladder Cancer
TON - June 2020, Vol 13, No 3
Read More ›
Enfortumab Vedotin plus Pembrolizumab Combination Leads to Impressive Responses in Patients with Urothelial Cancer
Enfortumab Vedotin plus Pembrolizumab Combination Leads to Impressive Responses in Patients with Urothelial Cancer
By Phoebe Starr
Bladder Cancer
TON - June 2020, Vol 13, No 3
Read More ›
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
FDA Updates, Lung Cancer
Web Exclusives
On May 29, 2020, the FDA approved ramucirumab (Cyramza; Eli Lilly) in combination with erlotinib (Tarceva) for first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. Ramucirumab was previously approved for several types of cancer, including, in combination with docetaxel, for metastatic NSCLC, after platinum-based chemotherapy. Read More ›
Zejula Receives New Indication as Maintenance Treatment for Patients with Advanced Ovarian Cancer
Ovarian Cancer
Web Exclusives
Improvement in progression-free survival observed in the PRIMA clinical trial results in FDA approval of an additional indication for niraparib as first-line maintenance treatment of all patients with advanced ovarian cancer whose disease has had a complete or partial response to first-line platinum-based chemotherapy. Read More ›

Page 129 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.